Sai Parenterals Limited (SAIPARENT)
₹502.15 -0.75% இன்றைய முடிவு விலை
சுருக்கம்
Sai Parenterals Limited closed at ₹502.15 on 12 Nov 2026, with an RSI(14) of 52.9 and a P/E of 90.80. On the daily chart it is in a range, with a technical score of 41/100 (neutral). Data as of 12 Nov 2026.
விலை
- விலை
- ₹502.15
- நாள் மாற்றம்
- -0.75%
- சந்தை மதிப்பு
- ₹2,218 கோடி
- 52-வார வரம்பு
- ₹400.00 – ₹706.00
- 52-வார உச்சத்திலிருந்து
- -28.87%
- 52-வார தாழ்விலிருந்து
- +25.54%
பங்குச் சந்தை செயல்பாடு12 நவ. 2026
- டெலிவரி
- 56.62% எதிர் சராசரி 51.81%
- வால்யூம் அதன் சராசரியுடன் ஒப்பீடு
- 0.4×
நிதிநிலை12 நவ. 2026
- P/E
- 90.80
- P/B
- 4.47
- ROE
- 4.9%
- ROCE
- 6.0%
- கடன்-டு-ஈக்விட்டி
- 1.02
- OPM
- 12.8%
- டிவிடெண்ட் ஈல்ட்
- 0.00%
சமீபத்திய காலாண்டு செப். 2026 · ஒருங்கிணைந்த
பங்கு உரிமைசெப். 2026
- புரமோட்டர்கள்
- 51.16%
- காலாண்டில் மாற்றம்
- +0.00 pp
- FII-கள்
- 2.85%
- காலாண்டில் மாற்றம்
- -1.18 pp
- DIIs
- 7.84%
- காலாண்டில் மாற்றம்
- -0.69 pp
செப்டம்பர் 2026 உடன் முடிவடைந்த காலாண்டுக்கான பங்குதாரர் விவரம்; சதவீதப் புள்ளிகளில் மாற்றங்கள்.
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 1 நவ. 2026
டெக்னிக்கல்ஸ்12 நவ. 2026
- போக்கு
- வரம்பு
- தொழில்நுட்ப மதிப்பெண்
- 41/100 · நடுநிலை
- MACD
- ஏற்றத்துக்கு சாதகமான (bullish)
- RSI (14)
- 52.92
- ADX (14)
- 16.84
- SuperTrend
- ஏற்றத்துக்கு சாதகமான (bullish)
- 20-நாள் SMA-உடன் ஒப்பீடு
- +3.88%
- 50-நாள் SMA-உடன் ஒப்பீடு
- +0.17%
- RS மதிப்பீடு
- 46.00
- அருகிலுள்ள சப்போர்ட்
- ₹491.68
- அருகிலுள்ள ரெசிஸ்டன்ஸ்
- ₹530.15
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Sai Parenterals Limited reported Q2 FY27 results on 1 Nov 2026: revenue ₹195 Cr, and net profit ₹10.5 Cr; the operating margin was 20.6%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY | QoQ |
|---|---|---|---|
| வருவாய் | ₹195 | — | +9.1% |
| செயல்பாட்டு லாபம் | ₹40.2 | — | +71.1% |
| நிகர லாபம் | ₹10.5 | — | +32.7% |
| EPS (₹) | 2.38 | — | +33.0% |
| செயல்பாட்டு லாப வரம்பு | 20.6% | — | — |
- வரிக்கு முந்தைய லாபத்தில் 38% மற்ற வருமானம் மற்றும் ஒருமுறை கிடைத்த வருமானங்களிலிருந்து வந்தது.
- லாபம் இருந்தும் H1 FY27 செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
- மார். 2026 முதல் கடன்கள் 52% உயர்ந்துள்ளன
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹9.9 கோடி லாபத்தில், ₹6.2 கோடி (62%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது.
நிர்வாகத்தின் முன்னறிவிப்புக்கு எதிராக: FY27 EBITDA லாப வரம்பு ஆக குறைந்தது 17% என முன்னறிவிக்கப்பட்டிருந்தது (07 நவ. 2026 கான்கால்); H1 FY27 17.1% ஆக பதிவானது, திட்டப்படி நடக்கிறது.
முடிவுகள் வெளியானதிலிருந்து பங்கு விலை: -3.8% (அறிவிப்புக்கு முந்தைய முடிவு விலை முதல் சமீபத்திய முடிவு விலை வரை).
SAIPARENT டெலிவரி சதவீதம்
க்கான NSE EOD தரவு
On Thu, 12 Nov 2026, 56.62% of the SAIPARENT shares traded on NSE were taken to delivery, against the stock's own 20-session average of 51.81%. That is close to its usual level. Volume was 0.4 times its average, well below normal.
கடந்த 5 அமர்வுகளில் டெலிவரி: 51.0% · 56.0% · 29.0% · 51.5% · 56.6%
பங்குச் சந்தை வெளியிட்டவற்றின் விளக்கம், பரிந்துரை அல்ல. "accumulation" அல்லது "லாங் பில்டப்" போன்ற பெயர்கள் எண்களில் உள்ள ஒரு வடிவத்தை குறிக்கின்றன. டெலிவரி எவ்வாறு பகுப்பாய்வு செய்யப்படுகிறது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Sai Parenterals submitted its Q2 FY27 earnings conference call transcript, highlighting a 9% QoQ revenue increase to ₹196 crore and H1 FY27 revenue of ₹376 crore (on track for its ₹750 crore FY27 target). EBITDA surged 67% sequentially to ₹41 crore with margins expanding to 21.1% from 13.7% in Q1. The company confirmed the completion of deploying ₹98.8 crore in IPO proceeds across two acquisitions: 60% in Saicriti Pharma (₹83.83 crore) and 60% in Sai Prathyak Laboratories (₹15 crore). Management reiterated that the new ₹215 crore injectable plant at Saicriti remains on track for completion in July 2027.
- Q2 FY27 consolidated revenue reached ₹196 crore, up 9% QoQ, with H1 FY27 total at ₹376 crore towards its ₹750 crore full-year guidance
- EBITDA grew 67% QoQ to ₹41 crore, expanding EBITDA margin to 21.1% from 13.7% in Q1
- Net profit after tax rose 33% QoQ to ₹10.5 crore, bringing H1 FY27 PAT to ₹18.4 crore
- Deployed ₹98.8 crore of IPO funds to acquire 60% stakes in Saicriti Pharma (₹83.83 crore) and Sai Prathyak Laboratories (₹15 crore)
- Targeting completion of the ₹215 crore Saicriti injectables facility by July 2027, scaling injectable capacity to 154.66 million units
Sai Parenterals published its investor presentation detailing business restructuring and growth metrics following the consolidation of Noumed Pharmaceuticals. The company outlined an ongoing Rs 571 crore capex programme (funded share of Rs 440 crore), representing ~113% of TTM revenue (Rs 506 crore). Long-term international contracts include an AUD 232 million OTC supply deal over up to 7.5 years and a USD 11 million 4-year anti-tuberculosis supply contract in the Philippines. Installed capacity is guided to expand from 1,160 million to 1,469 million units p.a. post-programme.
- Ongoing Rs 571 crore capex programme (~113% of TTM revenue), with company-funded share at Rs 440 crore.
- Installed capacity planned to increase from 1,160 million units p.a. to 1,469 million units p.a.
- Contracted international revenue includes AUD 232 million Australian OTC supply and USD 11 million 4-year Philippines contract.
- Acquired 74.64% stake in Noumed Pharmaceuticals for AUD 22 million, adding 451+ TGA dossiers.
- CDMO vertical contributed 63% of net revenue in FY26, up from 5% in FY23.
Sai Parenterals reported consolidated revenue of ₹196.1 crore for Q2 FY27, up 9.0% sequentially, while PAT grew 32.7% QoQ to ₹10.5 crore. H1 FY27 revenue reached ₹376.0 crore, meeting 50% of its full-year FY27 guidance of ₹750 crore. EBITDA expanded 67.4% QoQ to ₹41.4 crore with margins improving to 21.1% from 13.7% in Q1 FY27. Strategic execution progressed with deployment of ₹98.8 crore IPO proceeds to acquire 60% stakes in Saicriti Pharma and Sai Prathyak Laboratories, alongside completing the Unit III capacity expansion to 155 million units/month.
- Q2 FY27 revenue from operations grew 9.0% QoQ to ₹196.1 crore (H1 FY27 at ₹376.0 crore).
- EBITDA jumped 67.4% QoQ to ₹41.4 crore, expanding EBITDA margin from 13.7% to 21.1%.
- Completed Unit III expansion, increasing production capacity by 81% from 85.5 to 155 million units a month.
- Deployed ₹98.8 crore IPO proceeds: ₹83.83 crore into Saicriti Pharma and ₹15 crore into Prathyak Laboratories.
- Contracted Australian OTC supply with Noumed stands at AUD 232 million (~₹1,506 crore).
Sai Parenterals Limited has submitted its statement of deviation or variation under Regulation 32 for the quarter ended September 30, 2026, confirming zero deviation in the deployment of its IPO proceeds. The company raised Rs 2,850 million through an Initial Public Offer in March 2026, monitored by India Ratings & Research. Key allocations include Rs 330 million fully utilized for working capital and Rs 136.54 million deployed out of Rs 143.02 million for debt repayment. Additionally, funds are being channeled into equity investments in Saicriti Pharma (Rs 100 million utilized of Rs 838.34 million) and Prathyak Laboratories (Rs 150 million utilized).
- Total funds raised through IPO: Rs 2,850 million
- Deviation or variation reported for Q2 ended September 30, 2026: Nil
- Working capital allocation of Rs 330.00 million fully utilized (100%)
- Rs 100 million utilized out of Rs 838.34 million allocated for 60% equity in Saicriti Pharma
- Rs 136.54 million utilized out of Rs 143.02 million allocated for debt repayment
Sai Parenterals has completed the acquisition of a 60% equity stake in Prathyak Laboratories Private Limited for Rs 15 crore, funded from unutilised IPO proceeds. The acquisition replaces an originally planned greenfield R&D centre at Genome Valley, Hyderabad, adding 28 research scientists and an active pipeline of 150 SKUs across 86 molecules. Prathyak has been renamed Sai Prathyak Laboratories Private Limited and becomes a direct subsidiary. Sai Parenterals also holds a Right of First Refusal (ROFR) to acquire the remaining 40% at the same valuation using internal accruals.
- Acquired 60% stake in Prathyak Laboratories for Rs 15 crore, valuing the entity at Rs 25 crore
- Funded via unutilised net proceeds from the company's recent initial public offering
- Adds an operating R&D facility with 28 research scientists and 150 SKUs across 86 molecules
- Includes Right of First Refusal (ROFR) to acquire the remaining 40% stake at the same valuation
- Replaces planned greenfield R&D construction, avoiding setup delays
Sai Parenterals Limited announced key leadership appointments approved at its board meeting on September 30, 2026. The company appointed Mr. Arvind Gannimitta, who holds a Ph.D. and brings over 26 years of pharmaceutical operations experience, as Chief Operating Officer (COO). Additionally, Mr. Ashwani Singh Bisht was appointed as Company Secretary and Compliance Officer (KMP) following the resignation of Ms. Shivali Aggarwal effective September 30, 2026. The COO appointment strengthens operations oversight as the company navigates recent quarterly revenue of Rs 178.67 Cr (Jun 2026).
- Appointment of Mr. Arvind Gannimitta (Ph.D.) as Chief Operating Officer effective September 30, 2026, bringing over 26 years of pharmaceutical operations experience.
- Appointment of Mr. Ashwani Singh Bisht (Membership No. A72076) with over 12 years of professional experience as CS and Compliance Officer.
- Resignation of Ms. Shivali Aggarwal as CS and Compliance Officer finalized effective September 30, 2026, due to personal reasons.
- Board meeting commenced at 10:30 a.m. and concluded at 11:45 a.m. on September 30, 2026.
Sai Parenterals Limited announced the outcome and voting results of its 25th Annual General Meeting held on September 10, 2026. All 12 resolutions were approved by shareholders with requisite majority, including the adoption of FY26 financial statements and director re-appointments. Crucially, shareholders approved a variation in the objects/terms and an extension of the time period for utilizing IPO proceeds designated for capacity expansion, manufacturing upgrades, and an R&D centre. Additionally, material related-party transactions involving downstream loans and contracts with Australian step-down subsidiary Noumed Pharmaceuticals Pty Ltd were approved.
- All 12 resolutions approved with requisite majority at the 25th AGM held on September 10, 2026
- Approval granted for variation and timeline extension of IPO proceeds utilization for manufacturing upgrades and R&D
- Material related-party transactions approved for loans and operations with step-down subsidiary Noumed Pharmaceuticals Pty. Ltd (Australia)
- A total of 54 members attended the meeting conducted through Video Conferencing
Sai Parenterals' Australian subsidiary, Noumed Pharmaceuticals, has renewed its OTC supply contract with a leading Australian pharmacy network for a 3-year term valued at AUD 30 million (~₹204 crore). This adds approximately AUD 10 million (~₹68 crore) in recurring annual revenue and expands the group's total contracted Australian OTC supply book to AUD 232 million (~₹1,506 crore). While current supplies are sourced from third-party manufacturers earning distribution margins, the company plans to transition production to its Adelaide and Indian facilities to capture higher manufacturing margins.
- 3-year OTC supply contract renewed at AUD 30 million (approximately ₹204 crore)
- Translates to an annual contracted run-rate of ~AUD 10 million (~₹68 crore)
- Cumulative contracted OTC book in Australia reaches AUD 232 million (~₹1,506 crore)
- Plan to shift production in-house upon commissioning of Adelaide plant to boost margins
Sai Parenterals Limited has announced that its management will participate in an in-person group analyst and institutional investor meeting in Mumbai on August 31, 2026, starting at 10:00 AM. The interaction is hosted by Strategic Growth Advisors Pvt. Ltd. The company confirmed that discussions will rely strictly on publicly available information without disclosing any unpublished price sensitive information (UPSI).
- In-person group meeting scheduled for Monday, 31st August, 2026, at 10:00 AM onwards in Mumbai
- Interaction hosted by Strategic Growth Advisors Pvt. Ltd.
- Discussions to remain limited to publicly available information without sharing UPSI
Sai Parenterals Limited has announced its 25th Annual General Meeting (AGM) scheduled for September 10, 2026, at 11:00 AM IST via Video Conference. The company has fixed Thursday, September 3, 2026, as the record date/cut-off date for determining shareholder voting eligibility. Additionally, the Register of Members and share transfer books will remain closed from September 4, 2026, to September 10, 2026 (both days inclusive).
- 25th Annual General Meeting to be held on September 10, 2026, at 11:00 AM IST via VC/OAVM
- Cut-off/Record date for electronic voting set as September 3, 2026
- Book closure scheduled from September 4, 2026, to September 10, 2026 (both days inclusive)
Sai Parenterals has issued the notice for its 25th Annual General Meeting scheduled for September 10, 2026, along with its FY 2025-26 Annual Report. The report notes that FY26 consolidated revenue stood at ₹381 Crore, with Q4 FY26 contributing ₹198 Crore. The company operates 5 facilities with ~1,160 million units of annual installed capacity and highlighted the renewal of a ₹1,300 Crore Australian OTC supply agreement.
- 25th Annual General Meeting scheduled for September 10, 2026, via Video Conferencing
- Consolidated revenue for FY 2025-26 reached ₹381 Crore, supported by ₹198 Crore in Q4
- Annual manufacturing capacity stands at approximately 1,160 million units across 5 facilities
- Highlights renewal of a ₹1,300 Crore OTC medicines supply agreement in Australia via subsidiary Noumed
Sai Parenterals reported Q1 FY27 consolidated revenue of Rs. 182 crores, EBITDA of Rs. 27 crores (14.9% margin), and PAT of Rs. 8 crores, tracking toward full-year guidance of Rs. 750 crores at ~17% EBITDA margin. The Board approved redeploying Rs. 101.85 crores of IPO proceeds to acquire 60% stakes in Saicriti Pharma (Rs. 83.83 crores) and Prathyak Laboratories (Rs. 15 crores). The shift was driven by Hyderabad Industrial Lands Transformation Policy constraints at its existing sites. The Saicriti investment delivers 154.66 million units of injectable capacity (a 47% increase over original plan) targeting completion by April 2027, while the AUD 53 million Australia capex program remains on track.
- Q1 FY27 consolidated revenue stood at Rs. 182 crores with EBITDA of Rs. 27 crores (14.9% margin) and PAT of Rs. 8 crores.
- Reaffirmed FY27 revenue target of Rs. 750 crores with an expected EBITDA margin of approximately 17%.
- Redeploying Rs. 101.85 crores of IPO funds toward 60% stakes in Saicriti Pharma (Rs. 83.83 crores) and Prathyak Labs (Rs. 15 crores).
- Saicriti project delivers 154.66 million units of injectable capacity (+47% vs earlier plan) targeted for completion by April 2027.
- Australia AUD 53 million manufacturing facility is fully funded, targeting TGA licensing inspection by March 31, 2027.
Sai Parenterals has published the audio recording of its earnings conference call held on August 12, 2026, for the quarter ended June 30, 2026. This filing is a standard regulatory requirement under SEBI Listing Regulations. The recording provides management's perspective on the company's performance following a quarter (Mar 2026) where revenue reached Rs 198.0 cr with a PAT of Rs 13.0 cr. Investors can access the recording via the company's website to evaluate future growth guidance.
- Earnings call conducted on August 12, 2026, for the Q1 period ended June 30, 2026
- Audio recording made available via a public URL as per Regulation 30 of SEBI Listing Regulations
- Company reported a significant revenue jump to Rs 198.0 cr in Mar 2026 from Rs 96.0 cr in Dec 2025
- Net profit stood at Rs 13.0 cr for the quarter ended March 2026
Sai Parenterals has detailed a major structural shift, with export revenue surging from 3% in FY23 to 63% in FY26, primarily driven by the acquisition of Noumed (Australia). The company is executing a ₹571 crore capex program, which is approximately 1.5x its FY26 consolidated revenue of ₹381 crore. Key growth is anchored by a 7.5-year AUD 202 million exclusive supply agreement in Australia and a USD 11 million contract in the Philippines. While revenue grew 58% in FY26, consolidated EBITDA margins compressed to 10.2% from 24.1% in FY25 due to the Noumed integration and acquisition costs.
- ₹571 crore total capex program underway, with ₹440 crore funded by the company through IPO proceeds and grants.
- AUD 202 million (approx. ₹1,100+ cr) 7.5-year exclusive supply agreement in Australia effective July 1, 2026.
- Export revenue share increased to 63% in FY26 from 3% in FY23, with Australia accounting for 76% of exports.
- Installed capacity to expand from 1,160 million units to 1,469 million units p.a. post-expansion program.
- CDMO segment now contributes 63% of net revenue, growing at a 355.6% CAGR between FY23 and FY26.
Sai Parenterals reported a consolidated revenue of ₹182.4 crore for Q1 FY27, achieving 24% of its ₹750 crore annual revenue target. The company is pivoting its IPO fund utilization, redeploying ₹101.85 crore to acquire 60% stakes in Saicriti Pharma (a ₹215 crore injectable facility) and Prathyak Laboratories (an established R&D center) instead of greenfield projects. This strategic shift increases planned injectable capacity by 47% to 154.66 million units with only a one-month delay in completion (April 2027). Management maintained its FY27 guidance of ₹750 crore revenue with an EBITDA margin of approximately 17%.
- Consolidated revenue reached ₹182.4 crore in Q1 FY27, representing 24% of the ₹750 crore full-year target.
- Redeploying ₹83.83 crore of IPO proceeds to acquire a 60% stake in Saicriti Pharma, which is building a ₹215 crore EU-GMP/USFDA compliant facility.
- Acquiring a 60% stake in Prathyak Laboratories for ₹18.02 crore, gaining an R&D team of 65 personnel and a pipeline of 150 SKUs.
- Injectable capacity target increased by 47% to 154.66 million units compared to the original 105 million units planned in the IPO.
- Standalone PAT grew 975.1% YoY to ₹8.9 crore, while consolidated EBITDA margin improved 50 bps QoQ to 14.9%.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
